<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Allogene Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/allogene-therapeutics-inc</link>
<description>Latest news and press releases for Allogene Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 28 May 2026 21:02:04 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/allogene-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835454978dffbe2df0e27e0.webp</url>
<title>Allogene Therapeutics, Inc.</title>
<link>https://6ix.com/company/allogene-therapeutics-inc</link>
</image>
<item>
<title>Allogene Therapeutics Announces Planned CEO Succession</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-planned-ceo-succession</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-planned-ceo-succession</guid>
<pubDate>Thu, 28 May 2026 21:02:04 GMT</pubDate>
<description>Allogene Therapeutics Announces Planned CEO</description>
</item>
<item>
<title>Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update</guid>
<pubDate>Wed, 13 May 2026 20:02:00 GMT</pubDate>
<description>Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation ArmAt Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation</description>
</item>
<item>
<title>Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study</description>
</item>
<item>
<title>Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-showcases-momentum-with-clinical-and-platform-advancements-in-allogeneic-car-t-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-showcases-momentum-with-clinical-and-platform-advancements-in-allogeneic-car-t-at-aacr-2026</guid>
<pubDate>Mon, 20 Apr 2026 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif. Allogene’s presentations at AACR highlight the potential of allogeneic CAR T to expand access, simplify delivery, and enable broader a</description>
</item>
<item>
<title>Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-closing-of-dollar2004-million-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-closing-of-dollar2004-million-public-offering-of-common-stock</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously</description>
</item>
<item>
<title>Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted-cd19cd70-allogeneic-car-t-for-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted-cd19cd70-allogeneic-car-t-for-autoimmune-diseases</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and</description>
</item>
<item>
<title>Allogene Therapeutics Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten</description>
</item>
<item>
<title>Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-proposed-public-offering-of-dollar175-million-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-proposed-public-offering-of-dollar175-million-of-common-stock</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell,</description>
</item>
<item>
<title>Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-583percent-mrd-clearance-with-cemacabtagene-ansegedleucel-cema-cel-vs-167percent-in-observation-arm-in-first-line-consolidation-lbcl</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-583percent-mrd-clearance-with-cemacabtagene-ansegedleucel-cema-cel-vs-167percent-in-observation-arm-in-first-line-consolidation-lbcl</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction</description>
</item>
<item>
<title>Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13-2026</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13-2026</guid>
<pubDate>Fri, 10 Apr 2026 20:02:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell ly</description>
</item>
<item>
<title>Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Thu, 12 Mar 2026 20:02:00 GMT</pubDate>
<description>Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader Delivery of CAR T at Biologic-Like ScaleInterim Futility Analysis Evaluating MRD Clearance and Early Safety Results Planned for April 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID</description>
</item>
<item>
<title>Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update </title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update-2</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update-2</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)</description>
</item>
<item>
<title>Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the mark</description>
</item>
<item>
<title>Allogene Therapeutics Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-participation-upcoming-133000330</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-participation-upcoming-133000330</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi's 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, M</description>
</item>
<item>
<title>Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-positions-2026-program-133000470</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-positions-2026-program-133000470</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Dise</description>
</item>
<item>
<title>Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-favorable-result-223900935</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-favorable-result-223900935</guid>
<pubDate>Mon, 15 Dec 2025 22:39:00 GMT</pubDate>
<description>Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allog</description>
</item>
<item>
<title>Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-third-quarter-210500585</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-reports-third-quarter-210500585</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Australia and South Korea Expected to Open in early 2026Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Har</description>
</item>
<item>
<title>Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-alpha3-trial-140400167</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-alpha3-trial-140400167</guid>
<pubDate>Mon, 03 Nov 2025 14:04:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florid</description>
</item>
<item>
<title>Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-report-third-quarter-123000674</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-report-third-quarter-123000674</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the third quarter 2025 financial results and provide a business update on November 6, 2025, after the close of the market. The</description>
</item>
<item>
<title>Allogene Therapeutics Announces Participation in Upcoming Investor Conference</title>
<link>https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-participation-upcoming-123000102</link>
<guid isPermaLink="true">https://6ix.com/company/allogene-therapeutics-inc/news/allogene-therapeutics-announces-participation-upcoming-123000102</guid>
<pubDate>Wed, 27 Aug 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September. Citi's 2025 Biopharma Back to School SummitWednesday, September 37:30AM PT/10:30AM ET Any available webcasts will be posted to the Company's website at www.all</description>
</item>
</channel>
</rss>